What is Bachem?
Headquartered in Bubendorf, Switzerland, Bachem operates as a premier global specialist in the development and manufacturing of peptides and oligonucleotides. The company serves as an essential partner to the pharmaceutical and biotechnology sectors, providing comprehensive services that bridge the gap between early-stage research and commercial-scale production. Their expertise is anchored in advanced synthesis technologies, including solid-phase and liquid-phase peptide synthesis, which are vital for the production of modern genetic medicines and RNA therapeutics.
Bachem's market position is defined by its state-of-the-art production facilities and a commitment to rigorous regulatory compliance. By supporting a diverse clientele—from emerging biotech startups to established multinational pharmaceutical corporations—the company facilitates advancements in critical disease areas such as oncology, metabolic disorders, and cardiovascular health. Their integrated service model ensures that complex therapeutic candidates are transitioned efficiently from the laboratory to the global market.
How much funding has Bachem raised?
Bachem has raised a total of $633.7M across 1 funding round:
Share Placement
$633.7M
Share Placement (2021): $633.7M, investors not publicly disclosed
Key Investors in Bachem
Bachem
Undisclosed investor participating in the funding round.
Bachem
Undisclosed investor participating in the funding round.
Bachem
Undisclosed investor participating in the funding round.
What's next for Bachem?
Looking ahead, the recent capital allocation is expected to accelerate Bachem's strategic initiatives in capacity expansion and technological innovation. As the pharmaceutical industry shifts toward more complex, personalized medicine, the demand for high-quality peptide and oligonucleotide manufacturing is projected to rise significantly. Bachem is poised to leverage its financial strength to enhance its manufacturing infrastructure, ensuring it remains at the forefront of the industry's evolution.
The company's focus will likely remain on optimizing its supply chain resilience and deepening its scientific expertise to meet the stringent requirements of global regulatory bodies. By continuing to invest in cutting-edge technology platforms, Bachem aims to maintain its competitive advantage, ultimately driving long-term value for stakeholders while contributing to the development of life-saving therapies worldwide.
